Disability-Related Disparities in Screening for Intimate Partner Violence During the Perinatal Period: A Population-Based Study.

Background: Persons with disabilities are at higher risk of experiencing intimate partner violence (IPV) during the perinatal period than persons without disabilities. Although screening for IPV during the perinatal period is recommended by many organizations, little is known about screening rates for IPV by disability status.

Methods: Our objective was to compare rates of IPV screening during the perinatal period among persons with and without disabilities in the United States.

Efficacy and safety of microwave ablation in solitary kidney patients with T1a small renal masses.

Objectives: To assess the safety and efficacy of using microwave ablation (MWA) to treat solitary kidney (SK) patients with T1a renal cell carcinoma (RCC).

Methods: Retrospective analysis of a prospectively maintained database identified patients with T1a RCC with either congenital or acquired SK. Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine before MWA and after at 6 and 12 months post-procedure.

[Sclerosing pneumocytoma: an old disease with a rare presentation].

Pulmonary pneumocytoma, formerly known as sclerosing hemangioma, is a rare, benign tumor that frequently affects women in the 4th and 5th decades of life. Here we present the case of a 17-year-old patient with a diagnosis of sclerosing pneumocytoma with infrequent presentation.

Covalent Modification of p53 by ()-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one.

is commonly mutated in cancer, giving rise to loss of wild-type tumor suppressor function and increases in gain-of-function oncogenic roles. Thus, inhibition of mutant p53 and reactivation of wild-type function represents a potential means to target diverse tumor types. ()-1-(4-Methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one (NSC59984), first identified from a high-throughput screen, induces wild-type p53 signaling and antiproliferative effects while inhibiting mutant p53 gain-of-function activities.